Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)

Cancer

Volumn 119, Issue 9, 2013, Pages 1660-1668

  Ribera, Josep Maria ^a   García, Olga ^a   Grande, Carlos ^b   Esteve, Jordi ^c   Oriol, Albert ^a   Bergua, Juan ^d   González Campos, José ^e   Vall Llovera, Ferran ^f   Tormo, Mar ^g   Hernández Rivas, Jesús Maria ^h   García, Daniel ⁱ   Brunet, Salut ^j   Alonso, Natalia ^k   Barba, Pere ^l   Miralles, Pilar ^m   Llorente, Andreu ⁿ   Montesinos, Pau ^o   Moreno, Maria José ^p   Hernández Rivas, Jose Ángel ^q   Bernal, Teresa ^r  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ Hospital Madrid Norte Sanchinarro   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁿ HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^o HOSPITAL UNIVERSITARIO LA FE   (Spain)

^p Hospital Clinico de Malaga   (Spain)

^q HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^r HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

Burkitt's lymphoma or leukemia; human immunodeficiency virus; immunochemotherapy; prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE MARROW; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84876666611     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27918     Document Type: Article

References (30)

1. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012; 379: 1234-1244.
2. Linch DC,. Burkitt lymphoma in adults. Br J Haematol. 2012; 156: 693-703.
3. Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol. 2012; 156: 234-244.
4. Dunleavy K, Wilson WH,. How I treat HIV-associated lymphoma. Blood. 2012; 119: 3245-3255.
5. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA,. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012; 118: 3977-3983.
6. Oriol A, Ribera JM, Esteve J, et al. PETHEMA Group; Spanish Society of Hematology. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003; 88: 445-453.
7. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and non infected patients. Cancer. 2008; 113: 117-125.
8. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361-1392.
9. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.
10. Mitelman F, editor. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
11. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994.
12. Kaplan EL, Meier P,. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
13. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977; 35: 1-39.
14. Cox DR,. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
15. Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012; 30: 387-393.
16. Todeschini G, Bonifacio M, Tecchio C, et al. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol. 2012; 87: 22-25.
17. Hoelzer D, Hiddemann W, Baumann A, et al. High survival rate in adult Burkitt's lymphoma/leukemia and diffuse large B cell lymphoma with mediastinal involvement [Abstract]. Blood. 2007; 110: abstract 518.
18. Mohamedbhai SG, Sibson K, Marafioti T, et al. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index > 95%. Br J Haematol. 2011; 152: 175-181.
19. Dujmovic D, Aurer I, Radman I, et al. Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia. Acta Haematol. 2012; 127: 115-117.
20. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011; 22: 1859-1864.
21. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004; 100: 1438-1448.
22. Noy A,. Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol. 2010; 22: 443-448.
23. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS. 2010; 24: 851-856.
24. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003; 98: 1196-1205.
25. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 1492-1499.
26. Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007; 110: 2846-2854.
27. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
28. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012; 2012: 735392.
29. Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J,. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA LAL3/97 study. Haematologica. 2005; 90: 990-992.
30. Wästerlid T, Jonsson B, Hagberg H, Jerkeman M,. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma. 2011; 52: 2090-2096.